AbbVie/Roche's Venclexta (venetoclax) has produced a high overall response rate in chronic lymphocytic leukaemia patients with the 17p deletion mutation, a sub-group who do not respond well
Each year 8 May marks World Ovarian Cancer Day. This article highlights the signs to look out for, latest research and a genuine 'diary' experience from a US patient.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.